September 24th, 2010
Xience V Stent Still Strong at 2 Years
Larry Husten, PHD
Two large trials presented at TCT continue to demonstrate the long-term superiority of the everolimus-eluting stent (EES) over the paclitaxel-eluting stent (PES). Gregg Stone presented two-year outcomes from more than 3500 patients randomized in the SPIRIT IV trial to either the Xience V or the Taxus stents. At two years, the rate of target lesion failure — defined […]
NEJM Journal Watch — Recent Cardiology Articles- More Data Support Semaglutide for Obesity-Related HFpEF, Regardless of Diabetes Diagnosis
- A Novel Agent Fails to Improve Outcomes in Diabetic Cardiomyopathy
- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?